Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading 0.5% Higher

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) traded up 0.5% on Wednesday . The stock traded as high as $95.91 and last traded at $95.00. 1,280 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 2,954 shares. The stock had previously closed at $94.49.

Analysts Set New Price Targets

Separately, BTIG Research initiated coverage on shares of Zealand Pharma A/S in a report on Thursday, March 7th. They issued a "buy" rating for the company.

Zealand Pharma A/S Price Performance

The stock has a market cap of $4.89 billion, a price-to-earnings ratio of -52.20 and a beta of 0.63. The company's fifty day moving average price is $86.10 and its 200-day moving average price is $61.75.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.08). Zealand Pharma A/S had a negative net margin of 203.99% and a negative return on equity of 49.78%. The company had revenue of $3.35 million for the quarter, compared to analyst estimates of $1.97 million. On average, sell-side analysts forecast that Zealand Pharma A/S will post -2.56 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.